MPs have voted 305-301 that the UK should negotiate to remain part of the European Medicines Agency following Brexit.
MPs have voted 305-301 that the UK should negotiate to remain part of the European Medicines Agency following Brexit.
Vertex Pharmaceuticals is considering a final offer from NHS England on funding for its cystic fibrosis therapies, but said it remains concerned that the deal on the table does not fully reflect the value of its existing and future medicines for the condition.
Roche says its investigational flu drug baloxavir marboxil, in-licensed from Japan’s Shionogi, has met key goals in a late-stage trial.
Pfizer has kicked off a late-stage trial assessing efficacy and safety of the investigational gene therapy fidanacogene elaparvovec for the treatment of haemophilia B.
An independent ethics panel in the UK has concluded that genome editing to influence the characteristics of a future person could be “morally permissible”.
The National Institute for Health and Care Excellence has published a new guideline that aims to address current variation in the provision of services for adults with cerebral palsy.
European regulators have approved Akcea and Ionis’ Tegsedi for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
The all new Sales Awards offers a unique opportunity for sales professionals at all levels of their career to sharpen their skills and showcase their talents industry-wide.
The PharmaTimes Marketer of the Year competition offers a unique opportunity for all marketers, from aspiring to experienced, to sharpen their skills and showcase their talents against marketing professionals, industry-wide.
Sobi UK and Ireland has announced the launch of Kineret across the country offering a new treatment option for Adult Onset Stills Disease (AOSD) and Systemic-Onset Juvenile Idiopathic Arthritis (SJIA).
AstraZeneca’s biologic Fasenra will likely be funded on the NHS as a treatment for people with severe eosinophilic asthma.
US regulators have approved the first treatment designed to mitigate the impact of a potential outbreak of smallpox caused by bioterrorism.
UCB and Amgen have brought their bone-boosting drug Evenity back to US regulators for review, following an initial rejection in July last year.
“The ‘NHS Challenge’ is designed specifically for agencies that have strong experience in dealing with UK specific challenges,” says the executive steering group’s Eric Hansen.
PharmaTimes Media has announced the Medical & Scientific Excellence Awards as the latest addition to its highly prestigious portfolio of events – and now is the time to enter!